CGEM Stock Analysis: Buy, Sell, or Hold?
CGEM - Cullinan Therapeutics, Inc. Common Stock
$17.47
0.16 (0.95%)
▲
5d:
+28.32%
30d:
+24.93%
90d:
+36.02%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When CGEM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: CGEM is 10.4% above its trading range ($15.82). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: CGEM is 10.4% above its trading range ($15.82). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: CGEM is currently trading at $17.46, which is considered extended relative to its 30-day fair value range of $13.39 to $15.82.
Technical Outlook: Technically, CGEM is in a uptrend. The price is approaching resistance at $17.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CGEM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.55 (+82.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CGEM is in a uptrend. The price is approaching resistance at $17.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CGEM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.55 (+82.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.39 -
$15.82
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+10.4% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.3% below Wall St target ($31.55)
Trading Range Analysis
30-Day Trading Range
$13.39 -
$15.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.68
Resistance Level
$17.40
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.84
Wall Street Target
$31.55
(+82.3%)
Share & Embed Analysis
Last updated: June 23, 2026 11:11 AM ET
Data refreshes hourly during market hours. Next update: 12:11 PM
Data refreshes hourly during market hours. Next update: 12:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Jennifer Michaelson
SELL
8000 shares
2026-03-05
Jennifer Michaelson
SELL
1780 shares
2026-02-25
Jacquelyn L Sumer
SELL
3601 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 64 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 60 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
